Seller pressure near £14,350–£14,800 weighs on AstraZeneca stock price

Traders Union
All News
Financial News
AstraZeneca drops 2.31% to GBX14607.26

Highlights

AstraZeneca reported strong Phase III trial results for Ultomiris in IgA nephropathy and for tozorakimab in COPD, planning regulatory filings for both candidates.
Q1 2026 earnings showed a net profit margin of 17.41% and a $3.20 dividend per share, with all AGM proposals approved.
Despite positive fundamentals, shares face short- and medium-term selling pressure; current technicals indicate a likely GBX 14,350–14,800 trading range with longer-term bullish bias.

Positive trial outcomes and strong earnings offset by persistent selling

AstraZeneca reported positive Phase III interim results for Ultomiris in IgA nephropathy, achieving a significant reduction in proteinuria and meeting its primary trial endpoint, with plans to file for regulatory approval. The company also announced that tozorakimab reached its third consecutive Phase III success in the MIRANDA trial for COPD, and data submissions to regulators are underway. Q1 2026 earnings showed a net profit margin of 17.41% and return on equity at 22.68%, supporting a dividend of $3.20 per share and approval of all AGM resolutions, including KPMG LLP as auditor. These developments have occurred though price action has remained under broader selling pressure.

Weak momentum and oversold signals constrain upward potential

The MA-20 is at GBX 14,684.20 and MA-50 stands at GBX 14,760.60, with both above the current price; long-term support is more distant at the MA-200 of GBX 13,077.63. The Ichimoku Kijun, set at GBX 14,463.00, acts as immediate support. MACD on the daily chart remains positive with a Buy signal, while ADX is low at 14.83, suggesting weak trend intensity. RSI sits at 54.04 with a mild Buy bias, and Stoch RSI and CCI indicate neutral readings with recent oversold patterns intraday. BBP reflects overbought conditions on the daily timeframe, yet shows notable seller strength within intraday ranges.

Sideways range expected as breakout hinges on renewed buying

For the next several sessions, the typical volatility band is expected between GBX 14,350 and GBX 14,800. Weekly analysis of indicators such as RSI, ADX, MACD, and proximity to the MA-50 implies a strong probability of an upward move, exceeding 80%, with a scenario for a breakout above GBX 14,800 if buying resumes. The baseline case projects continued sideways activity within this corridor, while a bearish scenario would only be triggered by a decisive move below GBX 14,350, bringing the Ichimoku Kijun level into play as the next key support.

Viktoras Karapetjanc, expert at Traders Union, believes that AstraZeneca’s strong pipeline news and solid financials reinforce the stock’s longer-term quality, despite current market pressure. He sees momentum indicators signaling potential for a rebound, with fundamentals lending additional support. Analyst expects sideways movement near support, but the probability of an upward breakout is substantial if demand returns above GBX 14,800. "I remain positive on AstraZeneca’s prospects — strong fundamentals and continued R&D progress make a bullish reversal increasingly likely in the coming sessions."

Earlier, analysts noted that AstraZeneca's strong technical posture and ongoing progress in its drug development pipeline were supporting a constructive outlook despite intermittent selling pressure. The latest updates reinforce this view, with the risk-reward balance favoring an upside breakout if the price sustains above near-term support, making GBX 14,800 a key level to monitor for renewed momentum.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.